Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | DRD3 | P35462 | 5/20 | 0.61 |
| ▸ | HTR1D | P28221 | 3/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247469 | 1.00 | DRD2 (0.61) | DRD2DRD3HTR1DACHECA1 | |
| SCHEMBL9673238 | 0.83 | DRD2 (0.60) | DRD2DRD3HTR1DACHESTS | |
| SCHEMBL355640 | 0.83 | DRD2 (0.58) | DRD2DRD3HTR1DACHECA1 | |
| SCHEMBL346170 | 0.79 | DRD2 (0.57) | DRD2DRD3HTR1DACHECA1 | |
| SCHEMBL356130 | 0.77 | DRD2 (0.55) | DRD2DRD3HTR1DACHECA1 | |
| SCHEMBL8983525 | 0.77 | DRD2 (0.68) | DRD2DRD3ACHECA1CA2 | |
| SCHEMBL4427945 | 0.77 | STS (0.59) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL5026108 | 0.77 | STS (0.64) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL25214790 | 0.76 | DRD2 (0.46) | DRD2DRD3HTR1DDRD1DRD4 | |
| SCHEMBL8173009 | 0.76 | DRD2 (0.62) | DRD2DRD3HTR1DACHECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | DRD2 2063/4885DRD3 2383/4885HTR1D 1967/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | DRD2 1964/4885DRD3 2036/4885HTR1D 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.